Overview
This observational study is to develop and validate the prediction model for functional mitral regurgitation regression in heart failure patients taking GDMT. The patients diagnosed ≥2+ functional mitral regurgitation by ultrasonic cardiogram are enrolled in this study and would be clinically followed by at least one year (clinical visit at 3 months, 6 months, and 12 months), and then by when the endpoints are reached.
Eligibility
Inclusion Criteria:
- Age>18 years old
- ≥2+ FMR
- Receiving GDMT
Exclusion Criteria:
- degenerative mitral regurgitation
- myocardial infarction, percutaneous coronary intervention, coronary bypass grafting surgery, cardiac resynchronization therapy, or stroke within three months prior to this study
- ≥2+ aortic stenosis or regurgitation
- previous surgical mitral valve repair or replacement
- restrictive cardiomyopthy, hypertrophic cardiomyopathy, or constrictive pericarditis
- severe heart failure (NYHA class IV) or left ventricular ejection fraction < 20%
- symptomatic hypotension affecting GDMT prescription
- severe hepatic or renal insufficiency
- life expectancy < 12 months
- Pregnancy